Media Coverage and Costs of Newly Approved Medicines: What the Media Focuses On

Recent research conducted by the University of Eastern Finland and Fimea has shed light on how Finnish news outlets represent new medicines, particularly those used to treat obesity, cancer, mental health, and other conditions. Notably, GLP-1 agonists like semaglutide have garnered significant media attention, with 151 news articles discussing these drugs between 2013 and 2024. In contrast, many other new therapies, such as treatments for prostate cancer, Alzheimer's, and muscular dystrophy, received comparatively less coverage, despite their importance.

The study indicates that media visibility does not consistently align with the prevalence or costs of these medicines. For example, most of the medicines in the study, including GLP-1 agonists, have annual patient costs exceeding EUR 1,000, with some reaching up to EUR 1,300. The most expensive medication examined was ataluren for Duchenne muscular dystrophy, costing about EUR 442,000 annually per patient, and it was only briefly discussed in five articles. Conversely, vortioxetine, an antidepressant used by approximately 57,000 people annually, had the lowest patient-specific cost at around EUR 300, yet it was only covered in two articles.

The research highlights a disparity in media reporting, where certain medicines that are more expensive or have fewer users tend to receive less media attention. The findings suggest that this uneven coverage could influence public perception, medical decision-making, and healthcare funding priorities. The initial results were presented at the FIP World Congress in Copenhagen in 2025, offering insights into how Finnish media emphasizes specific medicines and their associated costs.

Understanding media portrayal of new medicines is crucial, as it impacts public understanding and policy-making. The next phase of the study will analyze how such medicines are discussed and communicated through media channels.

This investigation underscores the importance of balanced media reporting on new medical treatments, especially considering their costs and societal impact.

Source: https://medicalxpress.com/news/2025-09-media-visibility-medicines-highlight.html